Integrated Whole-Genome Analysis of Hematologic Disorders

This study is currently recruiting participants.
Verified October 2013 by Stanford University
Information provided by (Responsible Party):
Stanford University Identifier:
First received: April 19, 2010
Last updated: October 28, 2013
Last verified: October 2013

To identify mutations, changes in DNA copy number, structural rearrangements, or altered microRNA/mRNA expression that are important for the initiation, progression, or treatment response of hematologic disorders.

Condition Intervention
Hematologic Diseases
Procedure: Blood Draw
Procedure: Skin Biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA

blood, bone marrow, skin biopsy

Estimated Enrollment: 100
Study Start Date: September 2009
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

participants with hematologic disorders


Inclusion Criteria:

  1. 18 years of age or older
  2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
  3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

  1. Less than 18 years of age
  2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
  Contacts and Locations
Please refer to this study by its identifier: NCT01108159

Contact: Jason D Merker (650) 922-1885

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Jason D Merker    650-922-1885   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: James L Zehnder         
Sub-Investigator: Scott Boyd         
Sub-Investigator: Athena M. Cherry         
Sub-Investigator: Andrew Fire         
Sub-Investigator: Jason Robert Gotlib         
Sub-Investigator: Eleanor L. Marshall         
Sub-Investigator: Jason Merker         
Sub-Investigator: Stephen Tracy Oh         
Sponsors and Collaborators
Stanford University
Principal Investigator: James L Zehnder Stanford University
  More Information

No publications provided by Stanford University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Stanford University Identifier: NCT01108159     History of Changes
Other Study ID Numbers: HEM0013, 1081737-100-DHAAT, SU-09092009-3820, 16329
Study First Received: April 19, 2010
Last Updated: October 28, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hematologic Diseases processed this record on April 21, 2014